NANOVAXID* August 24, 2018

Design of novel anti-idiotype vaccines adjuvanted with RNA-based nanoparticles: entry into nanotechnology based personalized cancer immunotherapy

Go back

EuroNanoMed III is funded under the ERA-NET Cofund scheme of the Horizon 2020 Research and Innovation Framework Programme of the European Commission, Research Directorate-General, Grant Agreement No. 723770

Legal Mention

ENM III coordination unit

Instituto de Salud Carlos III (ISCIII)

  • Monforte de Lemos 5, 28029 – Madrid, Spain
  • era@isciii.es

Coordinator

  • Ignacio Baanante
  • ibaanante@isciii.es
  • +34 9182 22576
ENM III Call office

Instituto de Salud Carlos III (ISCIII)

  • Monforte de Lemos 5, 28029 – Madrid, Spain
  • ma.valencia@isciii.es
  • + 34 91 822 2227
Network Steering Committee Chair

VDI Technologiezentrum GmbH

  • Dr. Olaf Rotthaus
  • rotthaus@vdi.de
  • +49 211 6214 233

Ⓒ All rights reserved EuroNanoMed III, 2018